Around the world, millions of people are at an increased risk of illness or death from taking poor-quality medicines used to prevent or treat devastating illnesses. With funding from partners like the United States Agency for International Development (USAID), USP strengthens medicines quality assurance systems, increases the supply of quality-assured medicines, and develops capacity to detect and remove poor-quality medicines from the market. By sharing scientific expertise and providing technical support and leadership, we help local regulators improve and sustain local health systems, and enable manufacturers to supply quality-assured essential medicines for years to come. Through these efforts, we’re able to help prevent and treat diseases like HIV/AIDS, tuberculosis, malaria, and neglected tropical diseases, and improve maternal, newborn and child health.
Olakunle Ekundayo became a pharmacist to help others in need. And while his career ultimately took a different path, his role today as the CEO of a pharmaceutical manufacturing company has given him the opportunity to impact thousands of newborn lives in Nigeria, and beyond.
USP staff members across four offices in Africa and the United States share what it means to them personally to advance global public health through programs such as Promoting the Quality of Medicines Plus (PQM+), funded by USAID and implemented by USP.
The Promoting the Quality of Medicines Plus (PQM+) program, helps low- and middle-income countries strengthen the systems that ensure the quality and increase the supply of priority medicines. Funded by USAID, the PQM+ program is implemented by USP.
Millions of people around the world lack access to quality medicines. Medicines We Can Trust is a global collaborative campaign highlighting the human impact of poor-quality medicines and advocating for the right to safe and quality medicines for everyone, everywhere.
People around the world should be able to trust that the medicines they use to treat their illnesses won’t make them sicker. USP’s Emily Kaine shares her perspectives about the threat of poor-quality medicines to global health.
- Webinar: Robust regulatory systems: A critical enabler of local pharmaceutical development in Africa (Africa Pharma Conference)
- Webinar: How technology transfer can advance local production to improve access of quality-assured medical products in the time of COVID-19 (Africa Pharma Conference)
- Scaling Up African Pharmaceutical Manufacturing in a Time of COVID-19 (Council on Foreign Relations)
- COVID-19: USP offers guidance on strategic response model to African Regulatory Authorities (African Leadership Magazine)
- Low- and middle-income countries struggle with access to essential medicines (SupplyChainBrain.com)
- Integrating Medicines Quality Assurance into Universal Health Coverage Programming: A Path to Increasing Efficiency, Access, and Coverage
- Opinion: The hidden drain on universal health coverage gains and health care budgets (Devex)
- The next frontier for the public health medicines market: Advancing local pharmaceutical production to improve access to essential medicines
- Advising Morocco’s National Control Laboratory to support its successful quality re-certification
- The Case for Quality: Incentivizing Investments in Access to Quality Medicines (video)
- Strong regulatory systems critical to achieving positive health outcomes?(video)
- USP CDC AMR challenge commitment
- Scientific American highlights importance of medicine quality to fight antimicrobial resistance
- Poor-quality medicine: A global pandemic (A four-part series by Devex)